Fig. 4. Systemic treatment of Mito-Q ameliorated liver injury, bradykinesia, and mitochondrial dysfunction induced by BDL.
a Schematic flow chart to show the strategy. b H&E staining of BDL and Mito-Q (Bar = 100 μm or 30 μm). c–e The serum levels of ALT, AST, and TBil (n = 6 per group). f Ammonia levels in the blood (n = 6 per group). g Behavioral results of rotarod test (n = 10 per group). h Schematic traces of the open field test (n = 10 per group). i Analysis of the total distance, average speed, and the number of activities of the open field test (n = 10 per group). j SNr expression of UCP2, SOD1, and GPX1 from BDL and Mito-Q, assayed by western blot. k Quantitative analysis of j. l SNr expression of LC3B and PINK1 from BDL and Mito-Q, assayed by western blot. m Quantitative analysis of l. n SNr expression of DRP1, p-DRP1(Ser616), MFN2, MFF and FIS1 BDL and Mito-Q, assayed by western blot. o Quantitative analysis of n. Data are presented as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs TAA. n = 3 per group in western blotting. One-way ANOVA with LSD’s multiple comparison tests for all data. Source data are provided as a Source Data file.